Aurdan Capital Management LLC purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 9,043 shares of the medical research company's stock, valued at approximately $4,704,000. Thermo Fisher Scientific accounts for approximately 1.8% of Aurdan Capital Management LLC's investment portfolio, making the stock its 18th biggest position.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Stonegate Investment Group LLC increased its position in Thermo Fisher Scientific by 0.3% during the fourth quarter. Stonegate Investment Group LLC now owns 6,788 shares of the medical research company's stock worth $3,531,000 after acquiring an additional 18 shares during the period. Semus Wealth Partners LLC grew its position in shares of Thermo Fisher Scientific by 4.0% during the 4th quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock worth $245,000 after purchasing an additional 18 shares in the last quarter. Evernest Financial Advisors LLC raised its position in shares of Thermo Fisher Scientific by 4.0% in the fourth quarter. Evernest Financial Advisors LLC now owns 521 shares of the medical research company's stock valued at $271,000 after buying an additional 20 shares in the last quarter. Proactive Wealth Strategies LLC boosted its stake in shares of Thermo Fisher Scientific by 2.7% in the fourth quarter. Proactive Wealth Strategies LLC now owns 753 shares of the medical research company's stock valued at $392,000 after buying an additional 20 shares during the period. Finally, Cassaday & Co Wealth Management LLC grew its position in Thermo Fisher Scientific by 0.9% during the fourth quarter. Cassaday & Co Wealth Management LLC now owns 2,286 shares of the medical research company's stock worth $1,189,000 after buying an additional 20 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Thermo Fisher Scientific
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the sale, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. The trade was a 7.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president now owns 23,167 shares of the company's stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 14,075 shares of company stock worth $7,305,942. Company insiders own 0.33% of the company's stock.
Wall Street Analyst Weigh In
TMO has been the subject of a number of recent analyst reports. Citigroup cut their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, May 21st. Scotiabank decreased their target price on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a report on Friday, April 25th. Evercore ISI cut their price target on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Finally, Stifel Nicolaus decreased their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $607.43.
View Our Latest Stock Analysis on TMO
Thermo Fisher Scientific Price Performance
Shares of NYSE TMO traded up $1.00 during mid-day trading on Thursday, hitting $403.13. 2,498,062 shares of the stock traded hands, compared to its average volume of 1,877,222. The company has a market cap of $152.18 billion, a PE ratio of 24.39, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a twelve month low of $390.50 and a twelve month high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The firm has a 50 day simple moving average of $435.42 and a two-hundred day simple moving average of $502.00.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The business's revenue for the quarter was up .2% on a year-over-year basis. During the same period last year, the firm posted $5.11 earnings per share. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.
Thermo Fisher Scientific Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's payout ratio is currently 10.09%.
Thermo Fisher Scientific Company Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
See Also
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
